Swedish imaging biomarker SME providing quantitative PET/MRI services for drug safety validation, metabolic disease diagnostics, and immune cell tracking.
Antaros Medical is a Swedish SME specializing in imaging biomarker services for pharmaceutical drug development and clinical trials. They provide quantitative imaging solutions — particularly PET and MRI — to validate drug safety, measure treatment effects, and discover diagnostic biomarkers for metabolic and inflammatory diseases. Their work helps pharma companies and academic consortia translate imaging data into reliable endpoints for clinical decision-making, covering areas from diabetic kidney disease to liver steatohepatitis and immune cell tracking.
Central to all four projects: IB4SD-TRISTAN focuses on imaging biomarker validation for drug safety, Immune-Image on PET/MRI/optical immune cell imaging, and BEAt-DKD on imaging biomarkers for diabetic kidney disease.
IB4SD-TRISTAN (their largest grant at EUR 566K) is specifically about validating translational imaging methods for drug safety assessment across lung, rheumatology, and toxicology.
BEAt-DKD targets diabetic kidney disease biomarkers while LITMUS focuses on NAFLD/steatohepatitis marker utility — both metabolic conditions with overlapping patient populations.
Immune-Image (2019-2026) applies PET, MRI, optical, and biological tracers to visualize immune cell dynamics — their most recent and forward-looking project.
Their early H2020 work (2016-2017) centered on disease-specific biomarker discovery — diabetic kidney disease pathogenesis, personalized medicine, and clinical omics — with imaging as one tool among many. By 2019, the focus shifted decisively toward imaging technology itself: PET/MRI tracer development, optical imaging, and immune cell visualization. The trajectory shows a move from being a biomarker service provider within disease-focused consortia to becoming an imaging methodology specialist with broader applicability across therapeutic areas.
Antaros is moving from disease-specific imaging support toward becoming a cross-therapeutic imaging technology partner, particularly in immune and molecular imaging — making them relevant to any consortium needing quantitative imaging endpoints.
Antaros operates exclusively as a specialist participant, never as coordinator — consistent with an SME that provides a defined technical service (imaging biomarker expertise) to large pharma-academic consortia. Their 121 unique partners across 18 countries indicate they work in very large IMI-style consortia (averaging 30+ partners per project), bringing their niche capability to major multi-stakeholder efforts. This makes them an easy partner to onboard: they know their role, deliver a specific technical component, and have extensive experience navigating large consortium dynamics.
With 121 unique consortium partners across 18 countries, Antaros has one of the broadest collaboration networks relative to their project count — a direct result of participating in large IMI public-private partnership consortia involving major pharma companies and leading European medical centers.
Antaros occupies a rare niche: a dedicated imaging biomarker SME that bridges the gap between academic imaging research and pharmaceutical clinical development. While large CROs offer imaging as one service among many, Antaros brings deep specialization in quantitative PET/MRI biomarker validation — making them a credible partner for both IMI-scale drug safety programs and smaller disease-focused studies. Their Mölndal location (adjacent to AstraZeneca and Sahlgrenska University Hospital) places them at the heart of Sweden's pharmaceutical imaging ecosystem.
